Zinc Nitroprusside Nanomedicine Turns Cisplatin into Chemoimmunotherapy for Liver Cancer
Start here
A Xiamen University team led by Gang Liu, with Yang Zhang and Pan He, has developed a fully active zinc nitroprusside nanomedicine, ZnNO, that reprograms cisplatin into a chemoimmunotherapeutic agent for hepatocellular carcinoma. Published in Cell Biomaterials, the study shows ZnNO boosts cisplatin sensitivity by depleting glutathione and releasing nitric oxide, while zinc ions activate the PERK-eIF2α pathway, inducing endoplasmic reticulum stress and restoring immunogenic cell death. The work offers a mechanistic route to overcoming cisplatin resistance and weak immune response in liver cancer. What remains open is how the strategy performs beyond the reported study, including validation in further preclinical and clinical settings.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatXiamen University team develops ZnNO plus cisplatin strategy for hepatocellular carcinoma
Gang Liu, Yang Zhang and Pan He published a study in Cell Biomaterials developing fully active zinc nitroprusside nanomedicine ZnNO, which reprograms cisplatin into a chemoimmunotherapeutic agent for hepatocellular carcinoma. ZnNO enhances cisplatin sensitivity by depleting GSH and releasing NO, while Zn2+ activates the PERK-eIF2α pathway and induces endoplasmic reticulum stress, restoring immunogenic cell death.
Coverage and heat for this story
Reports so far 1·Heat now 5·Peak heat 10 (Oct 20 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.